RSI Overbought Stocks
ACLX is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
ARCELLX INC (ACLX) Stock Price & Overview
NASDAQ:ACLX • US03940C1009
Current stock price
115.05 USD
-0.05 (-0.04%)
At close:
115.05 USD
0 (0%)
After Hours:
The current stock price of ACLX is 115.05 USD. Today ACLX is down by -0.04%. In the past month the price increased by 0.63%. In the past year, price increased by 85.5%.
ACLX Key Statistics
52-Week Range47.8601 - 115.13
Current ACLX stock price positioned within its 52-week range.
1-Month Range114.34 - 115.13
Current ACLX stock price positioned within its 1-month range.
- Market Cap
- 6.728B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.07
- Dividend Yield
- N/A
ACLX Stock Performance
Today
-0.04%
1 Week
+0.19%
1 Month
+0.63%
3 Months
+66.88%
Longer-term
6 Months +32.26%
1 Year +85.50%
2 Years +130.01%
3 Years +169.56%
5 Years N/A
10 Years N/A
ACLX Stock Chart
ACLX Stock Screens
ACLX currently appears in the following ChartMill screener lists.
ACLX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ACLX. When comparing the yearly performance of all stocks, ACLX is one of the better performing stocks in the market, outperforming 92.98% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ACLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACLX. No worries on liquidiy or solvency for ACLX as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ACLX Earnings
On February 26, 2026 ACLX reported an EPS of -1.01 and a revenue of 1.65M. The company beat EPS expectations (4.54% surprise) and missed revenue expectations (-87.9% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.01
Revenue Reported1.654M
EPS Surprise 4.54%
Revenue Surprise -87.90%
ACLX Forecast & Estimates
23 analysts have analysed ACLX and the average price target is 113.36 USD. This implies a price decrease of -1.47% is expected in the next year compared to the current price of 115.05.
For the next year, analysts expect an EPS growth of 8.71% and a revenue growth 186.52% for ACLX
Analysts
Analysts55.65
Price Target113.36 (-1.47%)
EPS Next Y8.71%
Revenue Next Year186.52%
ACLX Groups
Sector & Classification
ACLX Financial Highlights
Over the last trailing twelve months ACLX reported a non-GAAP Earnings per Share(EPS) of -4.07. The EPS decreased by -103.5% compared to the year before.
Income Statements
Revenue(TTM)22.29M
Net Income(TTM)-228.93M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.9% | ||
| ROE | -56.9% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-16.09%
Sales Q2Q%-89.17%
EPS 1Y (TTM)-103.5%
Revenue 1Y (TTM)-79.35%
ACLX Ownership
Ownership
Inst Owners87.47%
Shares58.48M
Float49.49M
Ins Owners1.37%
Short Float %4.59%
Short Ratio0.91
ACLX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 368.574B | ||
| AMGN | AMGEN INC | 15.56 | 191.752B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 170.842B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.65 | 112.224B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.37 | 41.318B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.537B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.454B | ||
| BIIB | BIOGEN INC | 11 | 26.028B | ||
| UTHR | UNITED THERAPEUTICS CORP | 20.13 | 25.789B | ||
| MRNA | MODERNA INC | N/A | 21.305B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.501B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACLX
Company Profile
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Redwood City, California and currently employs 209 full-time employees. The company went IPO on 2022-02-04. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. The company is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Company Info
IPO: 2022-02-04
ARCELLX INC
800 Bridge Parkway
Redwood City CALIFORNIA US
Employees: 209
Phone: 12403270603
ARCELLX INC / ACLX FAQ
What does ACLX do?
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Redwood City, California and currently employs 209 full-time employees. The company went IPO on 2022-02-04. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. The company is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
What is the current price of ACLX stock?
The current stock price of ACLX is 115.05 USD. The price decreased by -0.04% in the last trading session.
Does ARCELLX INC pay dividends?
ACLX does not pay a dividend.
What is the ChartMill rating of ARCELLX INC stock?
ACLX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for ARCELLX INC?
ARCELLX INC (ACLX) operates in the Health Care sector and the Biotechnology industry.
What is the next earnings date for ACLX stock?
ARCELLX INC (ACLX) will report earnings on 2026-05-06, after the market close.
Who owns ARCELLX INC?
You can find the ownership structure of ARCELLX INC (ACLX) on the Ownership tab.